Currently, three main targets of CAR-T therapy for prostate cancer research are prostate specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), and epithelial cell adhesion molecule (EpCAM). The gene discussed is FOLH1; the disease is prostate cancer.